JOHNSON & JOHNSON is 279.1x more valuable than Immunome Inc. by market capitalization ($574.10 B vs $2.06 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMNM | JNJ |
|---|---|---|
| Market cap | $2.06 B | $574.10 B |
| US-listed rank | #2083 | #20 |
| Revenue (latest FY) | $6.94M | $94.19B |
| Net income (latest FY) | -$212.39M | $26.80B |
| Net margin | -3060.0% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 416 | 984 |
JOHNSON & JOHNSON is 279.1x more valuable than Immunome Inc. by market capitalization ($574.10 B vs $2.06 B).
In their latest fiscal years, Immunome Inc. reported $6.94M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Immunome Inc. and JOHNSON & JOHNSON, or browse the full rankings.